Aptamer Group Ltd, the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces that it has entered into a large-scale Optimer development and commercialisation agreement with a life science research company for over 250 targets.
The deal structure with a potential total value of multiple millions of pounds including upfront, phased payments throughout development and, further potential IP and commercial milestone payments as Optimer binders are incorporated into proteomic research products and kits.
The Optimer platform consists of three integrated discovery processes that together increase the potential target range of the oligonucleotide-based Optimer ligands, enabling the sensitive detection of novel targets in life sciences. This expanded target range can be applied to drive the understanding of how genes and proteins interact with the environment, improve the development of drugs and enhance the diagnosis of patients.
For the full story, please visit the Aptamer Group website.
